...
首页> 外文期刊>Translational research: the journal of laboratory and clinical medicine >Search for the potential 'second-hit' mechanism underlying the onset of familial hemophagocytic lymphohistiocytosis type 2 by whole-exome sequencing analysis
【24h】

Search for the potential 'second-hit' mechanism underlying the onset of familial hemophagocytic lymphohistiocytosis type 2 by whole-exome sequencing analysis

机译:通过全外显子组测序分析寻找潜在的“二次打击”机制,该机制是2型家族性吞噬性淋巴细胞组织细胞增生症发作的基础

获取原文
获取原文并翻译 | 示例

摘要

Familial hemophagocytic lymphohistiocytosis type 2 (FHL2), caused by perforin 1 (PRF1), is a genetic disorder of lymphocyte cytotoxicity that usually presents in the first 2 years of life and has a poor prognosis. Late onset of FHL2 has been sporadically reported, and the mechanism is largely unknown. A newly diagnosed FHL2 patient was detected to have compound mutations in both PRF1 alleles and positive Epstein-Barr virus (EBV) infection. Her brother carried the same mutations and EBV infection status but kept healthy. To search the potential unknown mechanisms, we performed whole-exome sequencing analysis. The patient and her asymptomatic brother carried the same heterozygous missense (c.916G>A) and frameshift mutation (c.65delC) in PRF1. Germline mutation analysis demonstrated that only the proband was exclusively detected with a homozygous missense mutation (S1006L) in the PCDH18 gene, whereas others were found to have a heterozygous mutation (S1006L) of PCDH18. The calculated stability (free energy) changes showed that the mutation of PCDH18 mainly destabilized the protein structure. Furthermore, the mutation (S1006L) could lessen the PCDH18-induced inhibition of target cell activation and reduce the apoptosis of T lymphocytes. This study is the first to perform whole-exome sequencing analysis to search the potential "second-hit" mechanism that underlies the onset of FHL2. A novel type of compound heterozygous mutation has been found in PRF1. The detection of the homozygous germline mutation in PCDH18 strongly argues that the presence of a "second" germline mutation besides the PRF1 gene might be potentially an important mechanism for triggering the onset of FHL2.
机译:穿孔素1(PRF1)引起的2型家族性吞噬性淋巴细胞组织细胞增生症(FHL2)是一种淋巴细胞细胞毒性的遗传性疾病,通常在生命的前2年出现,预后较差。 FHL2的起病较晚,已有零星报道,其机制尚不清楚。检测到一名新诊断的FHL2患者在PRF1等位基因和阳性爱泼斯坦-巴尔病毒(EBV)感染中均具有复合突变。她的兄弟具有相同的突变和EBV感染状态,但保持健康。为了搜索潜在的未知机制,我们进行了全外显子组测序分析。患者和她的无症状兄弟在PRF1中携带相同的杂合错义(c.916G> A)和移码突变(c.65delC)。胚系突变分析表明,仅先证者仅在PCDH18基因中检测到纯合错义突变(S1006L),而其他人则具有PCDH18的杂合突变(S1006L)。计算的稳定性(自由能)变化表明PCDH18的突变主要破坏了蛋白质结构的稳定性。此外,该突变(S1006L)可以减轻PCDH18诱导的靶细胞活化抑制,并减少T淋巴细胞的凋亡。这项研究是首次进行全外显子组测序分析,以寻找潜在的“第二击”机制,该机制是FHL2发作的基础。在PRF1中发现了一种新型的化合物杂合突变。在PCDH18中检测到纯合种系突变强烈认为,除PRF1基因外,“第二”种系突变的存在可能是触发FHL2发作的重要机制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号